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Introduction: Intracranial hemorrhage (ICH) is a common, life-threatening neurological 
pathology in aging patients, many of whom take antiplatelet medications with potential to 
worsen the hemorrhage. In the event of ICH, Thomas Jefferson University Hospital (TJUH) 
follows a protocol modeling the 2016 Neurocritical Care Society (NCS) joint guidelines for 
antiplatelet medication reversal. We analyzed pre- and post-NCS guideline data from TJUH for 
outcomes of non-operative ICH patients in order to tease out the potential benefits of this 
protocol. 
Methods: This retrospective cohort study took place from January 2016 – Jan. 2018 at a tertiary 
care center: TJUH. Patients included were 18 y.o., on antiplatelet therapy who, had CTs 
available for evaluation of expansion, and did not undergo surgical management. The primary 
outcomes measured for comparison were both the admission and discharge Glasgow Coma 
Scores (GCS), admission and discharge modified Rankin Scores (mRS), time to death, 
hematoma expansion, and in-hospital mortality. T-tests, the Kolmogorov-Smirnov-test, and Chi-
Square test for independence were used. 
Results: For pre- and post-protocol groups, no significant difference existed for GCS or mRS, at 
admission and discharge. There were no significant findings for in-hospital mortality and 
hemorrhage expansion.   
Discussion: TJUH established a protocol in line with the 2016 NCS joint guidelines for 
managing ICH in patients on antiplatelet therapies. This protocol recommends discontinuing 
antiplatelet therapy and not transfusing platelets in patients not receiving surgical management. 
We examined the protocol efficacy have found no significant differences in the pre- and post-
protocol groups, indicating patient outcomes may be equivalent.  
 
 
